Ublituximab and Ibrutinib for Previously Treated, Genetically High-Risk CLL: Results of the GENUINE Phase 3 Study
GENUINE, the first randomized phase 3 trial conducted to assess the addition of a novel agent, ublituximab, to ibrutinib in high-risk, relapsed/refractory chronic lymphocytic leukemia (CLL), evaluates ibrutinib monotherapy versus ublituximab and ibrutinib.
A Genetic Risk-Stratified Phase 2 Study of Fludarabine/Antibody Combinations in Symptomatic, Untreated CLL: Results from Cancer and Leukemia Group B (CALGB) 10404 (Alliance)
Clinical Outcomes of Patients with DLBCL, FL, and Richter Transformation Treated with Ibrutinib: A Real-World Experience of Off-Label Ibrutinib Use
Suboptimal Adherence to Guideline-Recommended Molecular Testing in Patients with Newly Diagnosed AML: Data from the Connect MDS/AML Disease Registry
December 2016 Vol 9, Special Issue: Payers’ Perspectives In Oncology: AVBCC 2016 Highlights - Conference Correspondent
Washington, DC—With tremendous changes occurring in healthcare and particularly in oncology, discussion about the current trends and demands facing stakeholders in optimizing value in cancer care dominated the Sixth Annual Conference of the Association for Value-Based Cancer Care, held September 27-29, 2016, and co-chaired by Michael Kolodziej, MD, National Medical Director, Managed Care Strategy, Flatiron Health, New York, NY; and Burt Zweigenhaft, BS, President, National Association of Specialty Pharmacy; and Editor-in-Chief, Value-Based Cancer Care.
Evaluation of Minimal Residual Disease in Relapsed/Refractory Multiple Myeloma Patients Treated with a Daratumumab-Based Regimen
In this analysis, researchers evaluate whether daratumumab can further reduce minimal residual disease when added to lenalidomide- and bortezomib-containing regimens in patients with relapsed/refractory multiple myeloma.
Meta-Analysis to Compare Efficacy of Treatment Regimens for Relapsed/Refractory Multiple Myeloma Patients
Phase II Study of Lenalidomide, Subcutaneous Bortezomib, and Dexamethasone (RsqVD) in Newly Diagnosed Multiple Myeloma
In an effort to determine whether lower peripheral neuropathy rates could be achieved, this study evaluated the efficacy and safety of subcutaneous bortezomib in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.
Budget Impact Analysis of Elotuzumab in Combination with Lenalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Payers have expressed concern about the rising costs of combination therapies in multiple myeloma. In an effort to address these potential concerns, a budget impact model was developed to estimate the 3-year costs of adding elotuzumab in combination with lenalidomide and dexamethasone to a health plan’s formulary.
Page 3 of 8
Results 21 - 30 of 80
Results 21 - 30 of 80